Grant of Options

CRISM Therapeutics Corporation

30 June 2026

 

30 June 2026

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

Grant of Options

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has granted options over ordinary shares of no par value ('Ordinary Shares') in the Company (the 'Options') on 30 June 2026 to certain directors as set out below.

Director	Total number of Ordinary Shares subject to option grant	Options exercise price	Vesting Period
Andrew Webb	504,000	10p	30 June 2026 - 30 June 2028
Chris McConville	408,798	10p	30 June 2026 - 30 June 2028
Gerry Beaney	99,999	10p	30 June 2026 - 30 June 2028

The awards have been made under the Company's existing EMI Share Option Plan.  The Options will vest as to one-third on grant, one-third on the first anniversary of grant and one-third on the second anniversary of grant.  The options will become exercisable on the second anniversary of grant and expire on 30 June 2036, being 10 years from the date of grant.

The grant of Options to the Executive directors was overseen by the Remuneration Committee which made recommendations to the Board based on its assessment of each executive's personal performance during 2025 and 2026.

- Ends -

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Executive Chairman Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)    Andrew Webb 2)    Gerald Beaney 3)    Chris McConville
2	Reason for the notification
a)	Position/status	1)    Executive Chairman 2)    Non-Executive Director 3)    Chief Scientific Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	CRISM Therapeutics Corporation
b)	LEI	213800XFW6MKVCHHPW88
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares with no par value
	Identification code	ISIN: VGG042401262
b)	Nature of the transaction	Grant of Options
c)	Price(s) and volume(s)		Director/PDMR Exercise Price Volume Andrew Webb £0.10 504,000 Gerald Beaney £0.10 99,999 Chris McConville £0.10 408,798
d)	Aggregated information
	- Aggregated volume	N/A
	- Price	N/A
e)	Date of the transaction	30 June 2026
f)	Place of the transaction	Outside a trading venue

 

END